Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2001-03-06
2003-05-27
Spear, James M. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S422000, C424S427000, C424S430000, C424S433000, C424S434000, C424S435000, C424S436000, C424S441000, C424S451000, C424S457000, C424S463000, C424S464000, C424S465000, C424S466000, C424S470000, C424S474000, C424S476000, C424S482000, C424S490000, C424S489000, C424S498000, C514S773000, C514S784000, C514S785000, C514S786000, C514S779000
Reexamination Certificate
active
06569463
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to pharmaceutical delivery systems for pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals, and diagnostic agents. In particular, the present invention provides compositions and dosage forms including solid carriers for improved delivery of pharmaceutical active ingredients.
BACKGROUND
Hydrophobic active ingredients, such as progesterone, cyclosporine, itraconazole and glyburide present delivery challenges due to their poor aqueous solubility and slow dissolution rate. Several conmmercial products of these hydrophobic drugs are available, the various products using different methods to try to enhance in vivo performance. One approach is size reduction by micronization, such as in Prometrium (micronized progesterone) and Micronase (micronized glyburide). Other approaches include size reduction in emulsion formulations, such as in Sandimmune (cyclosporine emulsion) and NeOral (cyclosporine microemulsion). These approaches suffer from several disadvantages. Micronization
anonization presents processing and stability challenges, as well as dissolution limitations, since the micronized
anosized drug still possesses a high degree of crystallinity. Liquid formulations present drug precipitation and packaging challenges, due to solvent evaporation. Moreover, non-solid formulations are more prone to chemical instability and capsule-shell incompatibility, leading to the possibility of leakage upon storage.
For hydrophilic active ingredients, the formulation challenges are different. Although these compounds are readily soluble in the aqueous gastrointestinal environment, they are poorly absorbed, due to poor membrane permeability and/or enzymatic degradation. Surfactants and lipophilic additives have been reported to improve membrane permeability; see, e.g., LeCluyse and Sutton, “In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement”,
Advanced Drug Delivery Reviews,
23, 163-183 (1997). However, these compositions fail to maintain effective levels and type of enhancers for bioacceptable absorption enhancement. Most solid dosage forms of hydrophilic active ingredients exhibit poor or no absorption of the active. Moreover, these non-solid formulations suffer from the disadvantages of chemical instability, leakage and capsule shell incompatibility as discussed above.
Solid carriers for pharmaceutical active ingredients offer potential advantages over micronized drugs, emulsions or solubilized formulations. Solid carriers, typically of size less than about 2 mm, can easily pass through the stomach, thus making the performance less prone to gastric emptying variability. Further, the problems of leakage and other disadvantages of liquid formulations are not present in solid carrier formulations. To date, however, such solid carrier formulations generally have been limited to a few specific drugs, due to difficulties in formulating appropriate drug/excipient compositions to effectively coat the active ingredient onto a carrier particle.
Conventional solid dosage forms of hydrophobic active ingredients, such as tablets, or multiparticulates in capsules, often exhibit slow and incomplete dissolution and subsequent absorption. These formulations often show a high propensity for biovariability and food interactions of the active ingredient, resulting in restrictive compliance/labeling requirements.
Due to the slow dissolution arid dependence on gastric emptying, solid dosage forms often delay the onset of some hydrophobic active ingredients.
Thus, there is a need for pharmaceutical compositions and dosage forms, and methods therefor, that do not suffer from the foregoing disadvantages.
SUMMARY OF THE INVENTION
It is an object of the invention to provide solid pharmaceutical compositions having active ingredients in a rapid dissolvable and more solubilized state herein.
It is another object of the invention to provide solid pharmaceutical compositions having more rapid dissolution upon administration to a patient.
It is another object of the invention to provide solid pharmaceutical compositions having more sustained and complete solubilization upon administration to a patient.
It is another object of the invention to provide solid pharmaceutical compositions capable of delivery a wide variety of pharmaceutical active ingredients.
It is another object of the invention to provide solid pharmaceutical compositions of coated substrate materials without the need for binders.
It is another object of the invention to provide solid pharmaceutical compositions having increased chemical stability of the active ingredient.
It is another object of the invention to provide solid pharmaceutical compositions capable of improving the absorption and/or bioavailability of a pharmaceutical active ingredient.
It is another object of the invention to provide solid pharmaceutical compositions having better protection of the upper gastrointestinal tract from untoward effects of the active ingredient.
It is another object of the present invention to provide solid pharmaceutical compositions capable of improving the palatability of or masking the taste of unpalatable pharmaceutical active ingredients.
In accordance with these and other objects, the present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered.
In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat includes at least one ionic or non-ionic hydrophilic surfactant. Optionally, the encapsulation coat can include a pharmaceutical active ingredient, a lipophilic component such as a lipophilic surfactant or a triglyceride, or both a pharmaceutical active ingredient and a lipophilic component.
In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat includes a lipophilic component, such as a lipophilic surfactant or a triglyceride. Optionally, the encapsulation coat can include a pharmaceutical active ingredient, an-ionic or non-ionic hydrophilic surfactant, or both a pharmaceutical active ingredient and a hydrophilic surfactant.
In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat includes a pharmaceutical active ingredient and an ionic or non-ionic hydrophilic surfactant; a pharmaceutical active ingredient and a lipophilic component such as a lipophilic surfactant or a triglyceride; or a pharmaceutical active ingredient and both a hydrophilic surfactant and a lipophilic component.
In another embodiment, the solid pharmaceutical composition includes a solid carrier, wherein the solid carrier is formed of at least two components selected from the group consisting of pharmaceutical active ingredients; ionic or non-ionic hydrophilic surfactants; and lipophilic components such as lipophilic surfactants and triglycerides.
In other aspects, the present invention also provides dosage forms of any of the solid pharmaceutical compositions, and methods of using the solid pharmaceutical compositions.
These and other objects and features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
REFERENCES:
patent: 4717569 (1988-01-01), Harrison et al.
patent: 4849227 (1989-07-01), Cho
patent: 4867984 (1989-09-01), Patel
patent: 5023108 (1991-06-01), Bagaria et al.
patent: 5340589 (1994-08-01), Stetsko et al.
patent: 5380535 (1995-01-01), Geyer et al.
patent: 5571533 (1996-11-01), Santus et al.
patent: 5573783 (1996-11-01), Desieno et al.
patent: 5624687 (1997-04-01), Yano et
Chen Feng-Jing
Patel Mahesh V.
Lipocine Inc.
Reed Dianne E.
Reed & Eberle LLP
Spear James M.
LandOfFree
Solid carriers for improved delivery of hydrophobic active... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solid carriers for improved delivery of hydrophobic active..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid carriers for improved delivery of hydrophobic active... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3040554